Clinical trial
Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With…
NCT00290615 · Herbert Hurwitz, Other · Completed
Key facts
| NCT number | NCT00290615 |
|---|---|
| Title | Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery |
| Official title | Phase II Study of Oxaliplatin, Capecitabine, Cetuximab, and Bevacizumab in the Treatment of Metastatic Colorectal Cancer |
| Lead sponsor | Herbert Hurwitz, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, cetuximab, capecitabine, oxaliplatin |
| Enrollment | 30 |
| Start date | Jan 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2011 |
| First posted | Feb 13, 2006 |
| Last update posted | May 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: